<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01992250</url>
  </required_header>
  <id_info>
    <org_study_id>CP-00-0011</org_study_id>
    <nct_id>NCT01992250</nct_id>
  </id_info>
  <brief_title>Cryoablation of Small Breast Tumors in Early Stage Breast Cancer</brief_title>
  <acronym>FROST</acronym>
  <official_title>Freezing Alone Instead of Resection Of Small Breast Tumors: A Study of Cryoablation in the Management of Early Stage Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanarus Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanarus Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines the use of cryoablation as an alternative to surgery in the treatment of
      early stage invasive breast cancer. The hypothesis is that cryoablation will complete
      ablation and destroy the tumor in a selected population of women who may otherwise be
      adequately treated with surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PURPOSE:

      To determine the rate of successful tumor ablation in patients treated with cryoablation and
      endocrine therapy in a subset of patients with early stage breast cancer.

      OUTLINE:

        1. Core Biopsy (Pre-Registration)

        2. Magnetic Resonance Imaging (Pre-Registration)

        3. Tumor Cryoablation

        4. Core Biopsy (Post-Cryoablation)

        5. Magnetic Resonance Imaging (Post-Cryoablation)

        6. Postoperative Follow-up

        7. Evaluation of outcomes
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor ablation occurence</measure>
    <time_frame>Within 6 months</time_frame>
    <description>Successful tumor ablation will be defined as absence of residual viable invasive or in situ carcinoma. Will be determined at 6-month post-cryoablation biopsy. Residual disease will require surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local tumor recurrence</measure>
    <time_frame>Within 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfactory breast cosmesis results</measure>
    <time_frame>5 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event assessment</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Low Risk - Age 70+</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Age 70+. Patients treated with the Visica 2 Treatment System, followed by adjuvant therapies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate Risk - Age 50-69</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Age between 50-69. Patients treated with the Visica 2 Treatment System, followed by adjuvant therapies</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Visica 2 Treatment System</intervention_name>
    <description>Cryoablation</description>
    <arm_group_label>Low Risk - Age 70+</arm_group_label>
    <arm_group_label>Moderate Risk - Age 50-69</arm_group_label>
    <other_name>Visica Breast Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 50

          2. Unifocal primary invasive breast carcinoma diagnosed by core needle biopsy

          3. Maximum tumor size ≤1.5 cm in its greatest diameter

          4. Ultrasound visible lesion(s)

          5. Clinically node negative, hormone receptor positive (+). HER2 negative (-), with &lt;25%
             intraductal component in the aggregate.

          6. Unilateral or bilateral disease meeting study criteria

          7. Physical and emotional ability to undergo baseline and follow-up breast MRIs and
             serial breast cosmesis analysis

          8. Patient agrees to receive a 5 year minimum course of endocrine therapy following
             cryoablation for control of systemic disease

        Exclusion Criteria:

          1. Prior treatment (e.g., open surgical biopsy, lumpectomy) of index cancer

          2. Ductal carcinoma in-situ with microinvasions (T1mic)

          3. Multifocal or multicentric invasive breast carcinoma

          4. Prior or planned neoadjuvant systemic therapy for breast cancer

          5. Tumor with ≥25% IDC components
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis R. Holmes, MD, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>90210 Surgery Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pamela Ellis</last_name>
    <phone>(925) 460-6080</phone>
    <email>clinical@sanarus.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Breastnet</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracey Peters</last_name>
      <phone>480-314-7600</phone>
      <email>tracey@breastnet.net</email>
    </contact>
    <investigator>
      <last_name>Belinda Barcley-White, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>90210 Surgery Medical Center</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerald Coronado</last_name>
      <phone>310-651-2050</phone>
      <email>gerald@drholmesmd.com</email>
    </contact>
    <investigator>
      <last_name>Dennis R. Holmes, MD, FACS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blanca Mendez, BSHS CRCII</last_name>
      <phone>626-218-0433</phone>
      <phone_ext>80433</phone_ext>
      <email>blmendez@coh.org</email>
    </contact>
    <contact_backup>
      <last_name>Luci Tumyan, MD</last_name>
      <phone>626-218-0433</phone>
      <phone_ext>80433</phone_ext>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Epic Care</name>
      <address>
        <city>Emeryville</city>
        <state>California</state>
        <zip>94608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shoko Abe, M.D.</last_name>
      <phone>510-629-6682</phone>
      <email>Shoko.Abe@epic-care.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diagnostic Center for Women, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael J Plaza, M.D.</last_name>
      <phone>305-740-5100</phone>
    </contact>
    <contact_backup>
      <last_name>Cristina Upegui</last_name>
      <phone>305-740-5100</phone>
      <phone_ext>2004</phone_ext>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Naples Community Hospital</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Prichard</last_name>
      <phone>239-624-8120</phone>
      <email>Patricia.Pritchard@nchmd.org</email>
    </contact>
    <investigator>
      <last_name>Sharla Patterson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ascension Crittenton Hospital</name>
      <address>
        <city>Rochester</city>
        <state>Michigan</state>
        <zip>48307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Cribbs</last_name>
      <phone>248-652-5626</phone>
      <email>michael.cribbs@ascension.org</email>
    </contact>
    <contact_backup>
      <last_name>Colleen Ellis</last_name>
      <email>Colleen.Ellis@ascension.org</email>
    </contact_backup>
    <investigator>
      <last_name>Peter J. Littrup, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie Shultz, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lankenau Medical Center</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Steinberg, BS, RN, OCN</last_name>
      <phone>484-476-2395</phone>
      <email>SteinbergS@MLHS.ORG</email>
    </contact>
    <contact_backup>
      <last_name>Elene Turzo, MSN, CRNP</last_name>
      <phone>484-476-2649</phone>
    </contact_backup>
    <investigator>
      <last_name>Ned Z Carp, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer L Sabol, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robin Ciocca, D.O.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liz Lorrell</last_name>
      <phone>401-444-2277</phone>
      <email>emorrell@lifespan.org</email>
    </contact>
    <investigator>
      <last_name>Robert Ward, M.D&gt;</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Knoxville Comprehensive Breast Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miranda Stinnett</last_name>
      <phone>865-583-1014</phone>
      <email>mstinnett@kcbc-center.com</email>
    </contact>
    <investigator>
      <last_name>Kamilia Kozlowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caryn Wunderlich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health Sciences Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79416</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Bisbee</last_name>
      <phone>806-775-8597</phone>
      <email>Melanie.Bisbee@umchealthsystem.com</email>
    </contact>
    <investigator>
      <last_name>Rakhshanda Rahman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ogden Regional Hospital</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Kunz</last_name>
      <phone>801-479-2067</phone>
      <email>joshua.kunz@mountainstarhealth.com</email>
    </contact>
    <investigator>
      <last_name>Jose Tamayo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2013</study_first_submitted>
  <study_first_submitted_qc>November 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cryoablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

